MiMedx Group, Inc (NASDAQ:MDXG) Receives $9.60 Consensus PT from Analysts

MiMedx Group, Inc (NASDAQ:MDXG) has been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $9.60.

MDXG has been the subject of a number of research analyst reports. Lake Street Capital cut their price target on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 20th. Cantor Fitzgerald cut their price target on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, February 17th. UBS Group set a $10.00 target price on MiMedx Group in a research note on Monday, February 23rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Finally, Wall Street Zen cut MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th.

MiMedx Group Stock Down 11.6%

Shares of MDXG stock opened at $3.43 on Tuesday. MiMedx Group has a 12 month low of $3.31 and a 12 month high of $7.99. The firm has a market cap of $509.60 million, a PE ratio of 10.72 and a beta of 1.65. The stock has a 50 day moving average of $4.49 and a 200-day moving average of $5.89. The company has a quick ratio of 3.92, a current ratio of 4.32 and a debt-to-equity ratio of 0.06.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The company had revenue of $118.10 million during the quarter, compared to analyst estimates of $106.78 million. On average, equities analysts predict that MiMedx Group will post 0.3 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Kemnay Advisory Services Inc. bought a new stake in MiMedx Group in the fourth quarter valued at about $48,000. State of Alaska Department of Revenue bought a new stake in MiMedx Group in the third quarter valued at about $54,000. Headlands Technologies LLC bought a new stake in MiMedx Group in the second quarter valued at about $72,000. Jain Global LLC bought a new stake in MiMedx Group in the fourth quarter valued at about $73,000. Finally, Virtu Financial LLC bought a new stake in MiMedx Group in the fourth quarter valued at about $78,000. 79.15% of the stock is owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.